Shire to develop D-Pharm's DP-VPA

Shire (LSE:SHP; SHPGY), will exclusively develop and market DP-VPA, an analog of valproic acid to treat epilepsy, bipolar disorder, and migraine prophylaxis. SHP will pay upfront fees in cash and equi...